Therapeutic safety and efficacy of triple-immunosuppressants versus dual-immunosuppressants in severe-to-critical COVID-19: a prospective cohort study in Bangladesh

Therapeutic safety and efficacy of triple-immunosuppressants versus dual-immunosuppressants in severe-to-critical COVID-19: a prospective cohort study in Bangladesh

Background Hyperinflammation-induced respiratory failure is a leading cause of mortality in COVID-19 infection. Immunosuppressants such as, Baricitinib and interleukin inhibitors are the drug-of-choice to suppress cytokine storm in COVID-19. Here, we compared the therapeutic safety and efficacy of t...

Full description

Bibliographic Details
Main Authors: Md Jahidul Hasan, Raihan Rabbani, Ahmad Mursel Anam, Shihan Mahmud Redwanul Huq
Format: Article
Language:English
Published: Taylor & Francis Group 2022-12-01
Series:Annals of Medicine
Subjects:
COVID-19
cytokine storm
immunosuppressant
baricitinib
tocilizumab
secukinumab
Online Access:https://www.tandfonline.com/doi/10.1080/07853890.2022.2039958

Internet

https://www.tandfonline.com/doi/10.1080/07853890.2022.2039958

Similar Items